Crinetics Pharmaceuticals, Inc. — Director's Dealing 2019

Feb 12, 2019

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2018-12-31

Reporting Person: Krasner Alan Seth (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-11-20	Common Stock	J	1470	$14.45	Acquired	3470	Direct

Footnotes

F1: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c).